This is the authors' abstract. We don't add key points for this paper.
Myelodysplastic syndromes (MDS) are a challenging group of diseases for clinicians and researchers, as both disease course and pathobiology are highly heterogeneous. In (suspected) MDS patients, multi-parameter flow cytometry can aid in establishing diagnosis, risk stratification and choice of therapy. This review addresses the developments and future directions of multi-parameter flow cytometry scores in MDS. Additionally, we propose an integrated diagnostic algorithm for suspected MDS.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Duetz et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: